Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-385-7 | CAS number: 58-55-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral: LD50 = 272 mg/kg bw, (rat, comparable to OECD 401; BASF AG 1983).
Inhalation: LC50 > 6.7 mg/L dust (rat, 4 hours, according to OECD 403; BASF AG 1989).
Dermal: LD50 > 2000 mg/kg bw (rat, comparable to OECD 402; BASF AG 1988).
The test compound is of moderate toxicity after single ingestion and of low toxicity after inhalation and a single skin contact.
Key value for chemical safety assessment
Additional information
There are valid data available for the assessment of the acute oral, inhalative and dermal toxicity of theophylline.
Oral
In an acute toxicity study conducted by Knoll AG/BASF AG (1983) according to a protocol similar to OECD 401, doses of 100 - 1000 mg/kg bw were administed to 10 Sprague-Dawley rats per group and per sex. The animals were observed for 14 days for lethality and clinical signs of intoxication. The LD50 is 272 mg/kg bw for males and females. Mortality and clinical signs such as increased respiratory frequency and eyelid closure appeared as from the dose of 215 mg/kg bw. In the high dose group, more severe clinical symptoms of toxicity such as clonic convulsions, accelerated respiration and salivation were observed. At necropsy anaemia and unspecific bleeding in the thymus was found. Higher doses can be tolerated when the substance is not given as a bolus.
Other acute oral LD50 levels in rat (225 mg/kg bw), guinea pig (183 mg/kg bw), rabbit (350 mg/kg bw) and mouse (235 mg/kg bw) were published in literature without additional data (NIOSH, 1994, RTECS XH3850000).
Additionally, in mice a LD50 of 332 mg/kg bw was observed and clinical signs were convulsions, profuse salivation and emesis was observed (Tarka, 1982, Crit. Rev. Toxicol., 9, 275 -312).
Inhalation
In an acute inhalation study conducted according to a protocol similar to OECD 403, groups of 5 Wistar rats per sex were treated by nose/head exposure to dust aerosol at concentrations of 2.39 and 6.7 mg/L (analytical) for 4 hours and observed for 14 days (BASF AG 1989). No mortality was observed. Clinical signs of toxicity included changes in respiration, such as irregular and accelerated respriration, gasping, as well as salivation and restlessness. No pathologic findings were noted with necropsy. The LC 50 value for dust aerosol was > 6 .7 mg/L.
Another acute inhalative study reported a LC50 in rats of < 36 mg/m³ after 4 hours exposure (Izmerov et al., 1982, Centre of International Projects, GKNT, Moscow; cited in Umweltforschungsplan des Bundesministers fuer Umwelt, Naturschutz und Reaktorsicherheit 1996).
Dermal
A 50 % solution of theophylline in olive oil was applied for 24 hours to the intact skin of Wistar rats (5 animals/sex/dose) under semiocclusive conditions. The observation period following administration was 14 days.
The LD50 for the dermal application was >2000 mg/kg bw. No mortality, no clinical symptoms, no alteration of body weight and no pathological findings in necropsied animals were observed (BASF AG 1988).
In humans mild signs of toxicity are headache, gastrointestinal disturbances, hypotension, irritability and insomnia. Severe symptoms imply tachycardia , arrhythmia, cardiac arrest, convulsions and serious neurological symptoms. Seizures and death have also occurred (IARC 1991; Stavric 1988, Food Chem. Toxicol., 26, 541-565; Ogilvie 1978, Clin. Pharmacokinet., 3, 267-293; Minton N.A. and Henry J.A. 1996, Human and Experimental Toxicology, 15, 471 -481; Winek C.L. et al., 1980, Forensic Sci. Int., 15, 233-236; Parr M.J. et al., 1990, Intesiv. Care Med., 16, 394 -398; Greenberg A. et al., 1984, Am. J. Med., 76, 854-860). Toxicity may be developed at serum levels of 20 -30 μg/ml, whereas at levels below 15 μg/ml generally no symptoms were observed (see Chapter 7.10.3).
Conclusion: In animal studies theophylline showed a high toxicity after oral uptake and a low acute toxicity after dermal and inhalative uptake. In humans adverse effects have been obsered after intentional overdosing. Thereby, theophylline toxicity principally affects the gastrointestinal, cardiovascular and central nervaus systems.
Justification for classification or non-classification
Based on the oral LD50 of ca. 272 mg/kg bw. for rats theophylline has to be classified "Xn, R22" (Harmfull if swallowed) according to EU Annex VI of directive 67/548/EEC and "Category 3" according to GHS classification for the oral route.
Based on the inhalative LC50 > 6.7 mg/L dust and on the dermal LD50 > 2000mg/kg bw., theophylline has not to be classified according to EU and GHS requirements for the inhalative (dust aerosol) and dermal route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.